Melanoma Treatment: Can Combining Radiation with Immunotherapy Improve Outcomes?
"A new study suggests concurrent radiotherapy and anti-PD-1 therapy could be a safe, effective strategy for metastatic melanoma."
Metastatic melanoma, a challenging form of skin cancer to treat, has seen significant advancements with the advent of immune-checkpoint inhibitors. These drugs, particularly those targeting programmed-death 1 (PD-1), have shown promise in improving survival rates. However, many patients still require additional treatments like radiation therapy (RT) at some point during their care.
Radiation therapy has long been used to target cancer cells directly, but emerging evidence suggests it can also trigger a systemic anti-tumor response known as the abscopal effect. This effect occurs when radiation not only destroys cancer cells in the treated area but also stimulates the immune system to attack cancer cells throughout the body. Combining immune-checkpoint inhibitors with radiation therapy is a logical strategy to harness both local and systemic anti-cancer effects.
A recent study investigated the safety and efficacy of combining RT with anti-PD-1 immunotherapy in patients with metastatic melanoma. By retrospectively analyzing patient data, researchers aimed to determine if this combination could lead to better outcomes without increasing toxicity.
Melanoma’s Reach and Immunotherapy
A 2025 statistics overview reports 104,960 new U.S. melanoma cases and 11,300 Canadian cases. It also reports survival rates of 89–94% alongside immunotherapy breakthroughs, though the supplied summary does not specify which patients or measure those rates represent. The Cancer Research Institute describes immunotherapy as increasing survival and shifting melanoma treatment globally, while its 2025 report focuses on the field’s move toward more personalized, accessible, and durable strategies.
Immunotherapy’s Gains and Limits
Immunotherapy and targeted therapies have significantly changed melanoma management and improved patient quality of life, according to a 2024 review. Yet immunotherapy does not benefit everyone: some patients have tumor growth after an initial response, and many do not respond. Reviews describe ongoing efforts to improve on single-agent approaches and note that alternative immunotherapies, including approaches beyond immune checkpoint inhibitors, are still evolving.
Decoding the Study: Combining Radiation and Immunotherapy
The study, conducted at a single institution, retrospectively collected data from 59 patients with metastatic melanoma who received anti-PD-1 immunotherapy (either pembrolizumab or nivolumab) between August 2014 and December 2015. Of these patients, 17 also received palliative RT to a total of 21 sites. The researchers then compared survival data, overall response rates, and the occurrence of toxicities between patients who received concurrent RT (IR group) and those who did not (NIR group).
- Toxicity: The acute and late toxicity profiles were similar between the two groups, indicating that adding RT to anti-PD-1 therapy did not significantly increase adverse effects.
- Response Rate: The objective response rate (complete or partial response) was significantly higher in the IR group (64.7%) compared to the NIR group (33.3%). This suggests that combining RT with anti-PD-1 therapy may enhance the treatment's effectiveness in shrinking tumors.
- Abscopal Effect: One patient in the IR group experienced a complete response that was compatible with an abscopal effect, meaning that the radiation not only affected the targeted tumor but also triggered a response in tumors outside the irradiated field.
- Survival: While the 6-month disease-free survival and overall survival rates were numerically higher in the IR group, the differences were not statistically significant.
Radiation and Checkpoint Inhibitors
A review of immune checkpoint inhibitors and radiotherapy reports that overall survival was superior in the combination group in some cited studies, even when metastasis progression-free survival was not statistically different from checkpoint inhibitor treatment alone. The review cautions that progression-free survival may be an inadequate surrogate for treatment effectiveness in this setting. A separate report describes 10 patients with metastatic melanoma brain metastases who received pembrolizumab or nivolumab with radiotherapy concurrently or less than one month before immunotherapy began.
Resistance Limits Durable Control
A 2026 narrative review identifies primary and acquired resistance to immune checkpoint inhibitors as major barriers to durable disease control in advanced melanoma. It examines clinical patterns of treatment failure, biological mechanisms, limitations of biomarkers, and implications for treatment. The source frames resistance as an ongoing challenge rather than establishing that combination treatment overcomes it.
Future Directions: Optimizing the Combination
This study contributes to the growing body of evidence supporting the potential of combining radiation therapy with immune-checkpoint inhibitors for cancer treatment. The results suggest that this combination can be safe and effective, but several questions remain.
Improved Outcomes, Unmet Needs
A 2023 review reports that immunotherapy has strikingly improved outcomes in advanced and high-risk melanoma. For advanced inoperable stage IV disease, it says median survival has increased from approximately six months to nearly six years. However, another review notes that some patients do not benefit from immunotherapy or experience tumor growth after an initial response. A 2025 expert panel discussion focuses on combination immunotherapies, biomarkers, and next steps in newly diagnosed advanced melanoma.
Triplet Therapies Under Investigation
A 2026 overview says melanoma research is increasingly focused on near-universal cure rates for early-stage disease and durable remission for advanced cases. To address treatment resistance, researchers are investigating triplet therapies combining immunotherapy, targeted therapy, and personalized vaccines. These are research directions described by the source, not established outcomes.
Complex Treatment Decisions
A review of advanced melanoma treatment describes management as involving multifaceted challenges and aims to help clinicians make informed treatment choices. Its listed topics include BRAF, immune-checkpoint inhibitors, LAG-3, PD-1, targeted therapy, and distinct melanoma types such as mucosal and uveal melanoma. The supplied summary does not specify particular systemic barriers or compare treatment outcomes across these groups.
Evidence Beyond Clinical Trials
A prospective Queensland cohort used 3D total-body photography to observe changes in naevi and describe advanced-stage melanoma patients receiving immunotherapy and/or targeted therapies in real-world care. A separate nationwide real-world study reports that survival outcomes with adjuvant anti-PD-1 aligned with randomized controlled trial results. In that study, patients who stopped therapy early for reasons other than recurrence had outcomes similar to those who completed planned treatment. Another real-world study highlights uncertainty about adjuvant therapy’s clinical benefit in older patients, who remain under-represented in trials and may face competing risks of death from other causes.
Further research is needed to determine the optimal timing and fractionation of RT in combination with anti-PD-1 therapy. Clinical trials are also needed to confirm these findings and to identify which patients are most likely to benefit from this approach.
As research continues to unravel the complex interplay between radiation and the immune system, we can expect to see further advances in the use of combined modality therapy for metastatic melanoma and other cancers. These advancements offer hope for improved outcomes and a better quality of life for patients facing these challenging diseases.